Compare DNP & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNP | PBLS |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 1995 | 2026 |
| Metric | DNP | PBLS |
|---|---|---|
| Price | $10.92 | $39.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 562.3K | 341.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $25.56 |
| 52 Week High | $11.16 | $41.49 |
| Indicator | DNP | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 63.27 |
| Support Level | $10.60 | $38.00 |
| Resistance Level | $10.93 | $41.49 |
| Average True Range (ATR) | 0.10 | 2.27 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 48.21 | 66.54 |
DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.